. Author manuscript; available in PMC: 2012 Jan 1.

Published in final edited form as: Gene Ther. 2011 Mar 17;18(7):734–742. doi: 10.1038/gt.2011.32

Table 1.

Role of IL-12 in protection from CNS demyelination by HSV-IL-2 recombinant virus.^a

	Mice with CNS demyelination/Total number of mice in treated group
	HSV-IL-2 + HSV-IL-12p70			IL-12p70 DNA immunization
CNS	1:1	1:10	1:100	1X	2X	3X
Brain	5/5 (100%)	0/5 (0%)	0/5 (0%)	1/5 (20%)	1/5 (20%)	0/5 (0%)
Optic nerve	3/5 (60%)	1/5 (20%)	0/5 (0%)	1/5 (20%)	1/5 (20%)	0/5 (0%)
Spinal cord	5/5 (100%)	0/5 (0%)	0/5 (0%)	1/5 (20%)	1/5 (20%)	0/5 (0%)

Mice were co-infected with 1:1,1:10, or 1:100 ratio of HSV-IL-2 to HSV-IL-12p70, while some mice were immunized 1X, 2X, or 3X and ocularly infected with 2×10⁵ PFU/eye of HSV-IL-2. The presence of demyelination in the optic nerves, spinal cords, and brains of 5 mice per group was assessed on day 14 post infection.